U.S., April 3 -- ClinicalTrials.gov registry received information related to the study (NCT07508787) titled 'A Study Comparing Siplizumab With Rabbit Anti-Thymocyte Globulin to Help the Body Accept a Kidney Transplant' on March 11.
Brief Summary: The goal of this clinical trial is to learn if siplizumab can prevent rejection of a kidney transplant in adult participants with end stage kidney disease. The main questions it aims to answer are:
How many adverse events do participants receiving two different doses of siplizumab have compared to rabbit anti-thymocyte globulin (rATG)?
How many participants successfully keep their kidney transplant after receiving siplizumab or rATG? This will be calculated as those participants that did not: di...